collagen type IV alpha 5 chainGenealiases: ASLN · ATS · ATS1 · CA54
Q-omics provides the consensus-scored COL4A5 profile across patient tissues and cancer cell-line models. COL4A5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, COL4A5 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, COL4A5 RNA expression shows 18,916 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, HNSC, and UVM as cancer lineages where COL4A5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL4A5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL4A5 survival associations across molecular data types. COL4A5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL4A5 RNA expression–survival associations across cancer types. High COL4A5 expression shows unfavorable associations in LUAD, STAD, KIRC, UVM, LGG and KIRP. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for COL4A5 RNA expression.
This table summarizes COL4A5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COL4A5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL4A5 shows lower tumor expression in KIRC, KICH, COAD, THCA and LUAD and higher tumor expression in HNSC. The HNSC box plot shows higher COL4A5 RNA expression in tumor versus normal tissue (log2 FC = +2.935, t-test p < 0.001).
This table shows molecular features associated with COL4A5 in patient tissues and cancer cell lines. In patient samples, COL4A5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, COL4A5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
